DK3464309T3 - Phosphoramidatnukleosidderivater som anticancermidler - Google Patents

Phosphoramidatnukleosidderivater som anticancermidler Download PDF

Info

Publication number
DK3464309T3
DK3464309T3 DK17728596.2T DK17728596T DK3464309T3 DK 3464309 T3 DK3464309 T3 DK 3464309T3 DK 17728596 T DK17728596 T DK 17728596T DK 3464309 T3 DK3464309 T3 DK 3464309T3
Authority
DK
Denmark
Prior art keywords
anticancing
agents
nucleoside derivatives
phosphoramidate nucleoside
phosphoramidate
Prior art date
Application number
DK17728596.2T
Other languages
English (en)
Inventor
Michaela Serpi
Magdalena Slusarczyk
Hugh Griffith
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Application granted granted Critical
Publication of DK3464309T3 publication Critical patent/DK3464309T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK17728596.2T 2016-06-01 2017-05-31 Phosphoramidatnukleosidderivater som anticancermidler DK3464309T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1609601.8A GB201609601D0 (en) 2016-06-01 2016-06-01 Phosphoramidate compounds
PCT/GB2017/051549 WO2017207986A1 (en) 2016-06-01 2017-05-31 Phosphoramidate nucleoside derivatives as anticancer agents

Publications (1)

Publication Number Publication Date
DK3464309T3 true DK3464309T3 (da) 2020-06-29

Family

ID=56410850

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17728596.2T DK3464309T3 (da) 2016-06-01 2017-05-31 Phosphoramidatnukleosidderivater som anticancermidler

Country Status (26)

Country Link
US (2) US10906929B2 (da)
EP (1) EP3464309B1 (da)
JP (2) JP7025351B2 (da)
KR (1) KR20190015353A (da)
CN (1) CN109195981A (da)
AU (1) AU2017273117B2 (da)
BR (1) BR112018074961A2 (da)
CA (1) CA3025440A1 (da)
CL (1) CL2018003404A1 (da)
DK (1) DK3464309T3 (da)
EA (1) EA036409B1 (da)
ES (1) ES2801448T3 (da)
GB (1) GB201609601D0 (da)
HR (1) HRP20200983T1 (da)
HU (1) HUE051335T2 (da)
IL (1) IL263121B (da)
MX (1) MX2018014859A (da)
MY (1) MY198880A (da)
PH (1) PH12018502606A1 (da)
PL (1) PL3464309T3 (da)
PT (1) PT3464309T (da)
SA (1) SA518400552B1 (da)
SG (1) SG11201810018TA (da)
SI (1) SI3464309T1 (da)
WO (1) WO2017207986A1 (da)
ZA (1) ZA201807652B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
KR20230098915A (ko) 2014-11-28 2023-07-04 뉴카나 피엘씨 항암제로서 새로운 2' 및/또는 5' 아미노산 에스테르 포스포르아미데이트 3'-디옥시아데노신 유도체
KR20220107319A (ko) 2016-05-31 2022-08-02 칼비스타 파마슈티컬즈 리미티드 혈장 칼리크레인 저해제로서 피라졸 유도체
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
HRP20220367T1 (hr) 2017-11-29 2022-05-27 Kalvista Pharmaceuticals Limited Oblici za doziranje koji sadrže plazmatski kalikrein inhibitor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
EP3762394A4 (en) * 2018-03-09 2021-12-08 Medivir Aktiebolag CANCER TREATMENT WITH (2,2-BISHYDROXYMETHYL) METHYLENE CYCLOPROPANE CLEOTIDES
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN110845560B (zh) * 2019-11-21 2021-08-24 广东中科药物研究有限公司 苯丙氨酸酰胺化的核苷酸衍生物及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309525A2 (en) 2000-07-13 2003-05-14 Micrologix Biotech, Inc. Synthesis and antiviral evaluation of nucleic acid based (nab) libraries
JP2008523082A (ja) 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗菌活性および抗癌活性を有するヌクレオチド
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
JP2012514657A (ja) 2009-01-09 2012-06-28 ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
PL3447061T3 (pl) * 2011-03-01 2022-01-31 NuCana plc Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
HRP20220911T1 (hr) 2013-09-11 2022-10-28 Emory University Sastav nukleotida i nukleozida i njihova uporaba
JP2017504572A (ja) 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
CA2947939A1 (en) 2014-05-28 2015-12-03 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
CN106470672B (zh) 2014-06-25 2019-11-05 努卡那生物医药有限责任公司 包括吉西他滨前药的制剂
KR20230098915A (ko) * 2014-11-28 2023-07-04 뉴카나 피엘씨 항암제로서 새로운 2' 및/또는 5' 아미노산 에스테르 포스포르아미데이트 3'-디옥시아데노신 유도체
RS59934B1 (sr) 2015-06-09 2020-03-31 Abbvie Inc Modulatori nuklearnih receptora (ror) za lečenje inflamatornih i autoimunih oboljenja
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds

Also Published As

Publication number Publication date
EA036409B1 (ru) 2020-11-06
SG11201810018TA (en) 2018-12-28
CN109195981A (zh) 2019-01-11
SI3464309T1 (sl) 2020-10-30
JP2022051936A (ja) 2022-04-01
US20190375779A1 (en) 2019-12-12
PL3464309T3 (pl) 2020-10-19
SA518400552B1 (ar) 2021-12-08
WO2017207986A1 (en) 2017-12-07
ZA201807652B (en) 2021-05-26
BR112018074961A2 (pt) 2019-03-12
KR20190015353A (ko) 2019-02-13
MX2018014859A (es) 2019-03-07
JP2019517510A (ja) 2019-06-24
HRP20200983T1 (hr) 2020-12-11
US20210130387A1 (en) 2021-05-06
JP7025351B2 (ja) 2022-02-24
PT3464309T (pt) 2020-06-23
HUE051335T2 (hu) 2021-03-01
US10906929B2 (en) 2021-02-02
MY198880A (en) 2023-10-02
IL263121B (en) 2021-10-31
AU2017273117B2 (en) 2021-02-04
GB201609601D0 (en) 2016-07-13
EP3464309A1 (en) 2019-04-10
IL263121A (en) 2018-12-31
ES2801448T3 (es) 2021-01-11
EA201892745A1 (ru) 2019-05-31
AU2017273117A1 (en) 2018-12-06
EP3464309B1 (en) 2020-06-10
CA3025440A1 (en) 2017-12-07
PH12018502606A1 (en) 2019-10-21
CL2018003404A1 (es) 2019-04-05

Similar Documents

Publication Publication Date Title
DK3464309T3 (da) Phosphoramidatnukleosidderivater som anticancermidler
ZA201705092B (en) Substituted nucleoside derivatives useful as anticancer agents
DK3464271T3 (da) Pyrazolderivater som plasma-kallikreininhibitorer
DK3394033T3 (da) Heterocykliske forbindelser som immunmodulatorer
DK3319956T3 (da) Substituerede oxopyridinderivater
DK3324977T3 (da) Benzodiazepinderivater som rsv-inhibitorer
DK3464249T3 (da) Substituerede carbonnukleosidderivater, der er anvendelige som anticancermidler
DK3122752T3 (da) 4'-substituerede nukleosidderivater som hiv-reverse transskriptasehæmmere
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3094631T3 (da) Pyrimidinyloxybenzenderivater som herbicider
DK3294713T3 (da) Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
DK3331863T3 (da) Hidtil ukendte forbindelser som ror-gamma-modulatorer
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
CL2018001672A1 (es) Formulaciones para derivados de fosforamidato de farmacos nucleosidos.
DK3153508T3 (da) Naphthofuranderivater til anvendelse som anticancermidler
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
DK3792251T3 (da) Hidtil ukendte sulfonylaminobenzamidforbindelser som anthelmintika
MA49708A (fr) Dérivés de dihétérocycle liés à cycloalkyle
DK3372589T3 (da) Pyrimidinderivat
DK3319970T3 (da) Pyrido-oxazinonderivater som tnap-hæmmere
DK3233862T3 (da) Imidazopyridazinderivater som pi3k-beta-inhibitorer
DK3244717T3 (da) Jordbearbejdningsredskab
DK4056557T3 (da) Benzazepinderivater nyttige som medikamenter